之江生物
(688317)
| 流通市值：31.23亿 | | | 总市值：31.23亿 |
| 流通股本：1.92亿 | | | 总股本：1.92亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 137,579,847.2 | 94,595,921.31 | 51,227,345.41 | 274,333,302.55 |
| 营业收入 | 137,579,847.2 | 94,595,921.31 | 51,227,345.41 | 274,333,302.55 |
| 二、营业总成本 | 130,299,732.01 | 52,452,433.4 | 17,171,479.82 | 262,813,916.58 |
| 营业成本 | 37,975,715.52 | 24,058,757.59 | 12,461,980.48 | 95,680,295.79 |
| 税金及附加 | 5,543,379.06 | 3,763,126.43 | 1,776,765.36 | 6,196,747.9 |
| 销售费用 | 49,172,418.13 | 34,657,982.04 | 17,470,695.11 | 95,208,091.21 |
| 管理费用 | 65,799,975.27 | 44,789,917.79 | 18,697,810.27 | 89,509,965.88 |
| 研发费用 | 39,074,589.3 | 24,401,863.08 | 12,145,804.86 | 61,003,822.15 |
| 财务费用 | -67,266,345.27 | -79,219,213.53 | -45,381,576.26 | -84,785,006.35 |
| 其中:利息费用 | 226,586.94 | 165,759.36 | 70,705.45 | 351,598.51 |
| 其中:利息收入 | 78,707,993.16 | 73,997,614.83 | 44,271,028.69 | 67,541,068.09 |
| 资产处置收益 | 39,305.59 | 39,305.59 | 39,305.59 | - |
| 资产减值损失(新) | -25,242,978.05 | -14,494,431.28 | -3,486,897.84 | -186,453,781.91 |
| 信用减值损失(新) | -215,377.15 | -1,046,973.26 | -420,869.85 | -2,359,686.44 |
| 其他收益 | 8,193,886.12 | 3,541,272.3 | 1,217,737.8 | 27,795,326.24 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -9,945,048.3 | 30,182,661.26 | 31,405,141.29 | -149,498,756.14 |
| 加:营业外收入 | 67,466.24 | 36,473.64 | 25,056.37 | 1,079,368.21 |
| 减:营业外支出 | 1,066,383.99 | 922,052.06 | 150.35 | 8,213,469.58 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -10,943,966.05 | 29,297,082.84 | 31,430,047.31 | -156,632,857.51 |
| 减:所得税费用 | 2,065,622.89 | 3,292,120.33 | 4,523,132.97 | -19,775,784.17 |
| 六、净利润 | -13,009,588.94 | 26,004,962.51 | 26,906,914.34 | -136,857,073.34 |
| 持续经营净利润 | -13,009,588.94 | 26,004,962.51 | 26,906,914.34 | -136,857,073.34 |
| 归属于母公司股东的净利润 | -13,009,588.94 | 26,004,962.51 | 26,906,914.34 | -136,857,073.34 |
| (一)基本每股收益 | -0.07 | 0.14 | 0.14 | -0.71 |
| (二)稀释每股收益 | -0.07 | 0.14 | 0.14 | -0.71 |
| 八、其他综合收益 | -3,191,985.54 | -2,849,646.28 | -5,158,595.36 | -7,874,922.49 |
| 归属于母公司股东的其他综合收益 | -3,191,985.54 | -2,849,646.28 | -5,158,595.36 | -7,874,922.49 |
| 九、综合收益总额 | -16,201,574.48 | 23,155,316.23 | 21,748,318.98 | -144,731,995.83 |
| 归属于母公司股东的综合收益总额 | -16,201,574.48 | 23,155,316.23 | 21,748,318.98 | -144,731,995.83 |
| 公告日期 | 2024-10-30 | 2024-08-29 | 2024-04-29 | 2024-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |